However, its efficacy and advantage over crizotinib as first-line systemic therapy for patients with advanced ALK-positive NSCLC was demonstrated in the CROWN study (median PFS not reached vs. 9.3, HR = 0.28, p < 0.001) [25]. This evidence concerns the gene ALK and non-small cell lung carcinoma.